Navigation Links
Liponex Inc. Reports Further Analysis of CRD5 Phase I/II Clinical,Trial Data

OTTAWA, April 11 /CNW/ - Liponex Inc. (TSX:LPX), a biopharmaceutical company specializing in developing advanced products related to High Density Lipoprotein (HDL), often called "good cholesterol," today announced information from further analysis of the Phase I/II Clinical Trial of its lead product, CRD5. CRD5 is being developed for the treatment of dyslipidemia and heart disease.

A detailed review of patient information indicated that all blood chemistry and blood pressure measurements were within the normal or expected ranges. CRD5 was shown to be safe in dyslipidemic patients. In addition, the drug was well-tolerated in the patient group, with the exception of the reported GI adverse events that led to the cessation of the 5 gram dosing phase.

As previously reported, the overall mean HDL increase was 5% at both the 1g (n=50) and 3g (n=40) dosing levels but the patient to patient variation was high. While some patients had a negative response, over 20% of patients achieved more than a 10% rise in HDL at the lower dose levels.

The patient information was reviewed to determine if there were any patient characteristics that had an impact on the efficacy of CRD5. Some patients were taking other medications during the trial that may have had lipid altering effects and these subjects appeared to have reduced response to CRD5. Data from these subjects were removed and the trial results were reanalyzed. CRD5 appeared to be more effective in patients with baseline plasma HDL-cholesterol levels of less than 0.9 mM. This level of HDL is considered to be abnormal and is associated with elevated risk of developing heart disease. Those patients (n=17) with starting HDL levels below 0.9 mM averaged an 11% increase in HDL levels from baseline at the 3 gram CRD5 dosing level.

Of note, several patients were identified to have taken proton pump inhibitors (PPI), such as ranitidine and lansoprazole,
'"/>




Page: 1 2 3

Related medicine technology :

1. Liponex Inc. Reports Phase I/II Clinical Trial Data for CRD5
2. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
3. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
4. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
5. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
6. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
7. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
8. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
9. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
10. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
11. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Liponex Inc Reports Further Analysis CRD5 Phase Clinical Trial Data
(Date:9/2/2015)... 2, 2015   Gulf Coast Tattoo Removal is the ... cutting-edge Astanza Duality laser in Southern Mississippi . ... tattoo regret and take back control of their skin. The clinic ... its services to Biloxi , Gulfport ... tattoo regret being as prevalent as it is, I was surprised ...
(Date:9/2/2015)... SAN DIEGO , Sept. 2, 2015  Neurocrine ... Tim Coughlin , Chief Financial Officer of Neurocrine ... Conference in New York City . ... September 9 at 11:25am ET (8:25am PT).  The presentation ... Company,s website at http://www.neurocrine.com .   ...
(Date:9/2/2015)... 2015  ArmaGen, Inc., a privately held biotechnology ... severe neurological disorders, announced today that the first ... 1/2a clinical trial of AGT-181 in patients with ... AGT-181 is an investigational enzyme replacement therapy ... most severe form of MPS I, Hurler syndrome, ...
Breaking Medicine Technology:Gulf Coast Tattoo Removal Delivers Unrivaled Tattoo Removal Results To Biloxi And Gulfport With Astanza Duality 2ArmaGen Announces First Patient Dosed in Phase 1/2a Clinical Trial of AGT-181 for the Treatment of Hurler Syndrome 2ArmaGen Announces First Patient Dosed in Phase 1/2a Clinical Trial of AGT-181 for the Treatment of Hurler Syndrome 3ArmaGen Announces First Patient Dosed in Phase 1/2a Clinical Trial of AGT-181 for the Treatment of Hurler Syndrome 4
(Date:9/2/2015)... ... September 02, 2015 , ... Ericson is a noted ... Director for HCPro and Associate Director of Education for the Association for Clinical Documentation ... and ICD-10 for CDI Boot Camps. She serves as a CDI subject matter expert ...
(Date:9/2/2015)... ... 2015 , ... A third party administrator (TPA) based in ... significant increase in unlawful tactics used by out-of-network (OON) ambulatory surgical centers (ASCs). ... ASCs encouraging members to have elective procedures done at their facilities with the ...
(Date:9/2/2015)... ... 02, 2015 , ... The 2015 China Overseas Investment and ... business conference will be hosted at five star Beijing Kunlun Hotel and Diaoyutai ... will feature leading EB-5 industry professionals and Chinese private equity partners looking for ...
(Date:9/2/2015)... ... 2015 , ... Amada Senior Care, premier provider of in-home care and assisted ... County location. Amada franchise partners Mike and Mell Fleming came to the senior ... over 20 years in medical device sales while Mell spent over 30 years as ...
(Date:9/2/2015)... Lakeland, FL & Minneapolis, MN (PRWEB) , ... ... ... device company that is commercializing products for the upper extremity surgical market, announced ... Trigger Tome® surgical instrument for trigger releases in the hand. Plus, nearly ...
Breaking Medicine News(10 mins):Health News:ezDI Names Noted CDI Educator Cheryl Ericson as Company’s Clinical Documentation Manager 2Health News:ezDI Names Noted CDI Educator Cheryl Ericson as Company’s Clinical Documentation Manager 3Health News:ezDI Names Noted CDI Educator Cheryl Ericson as Company’s Clinical Documentation Manager 4Health News:TPA Cracks Down on Forbidden Tactics Used by Out-of-Network Surgical Centers 2Health News:TPA Cracks Down on Forbidden Tactics Used by Out-of-Network Surgical Centers 3Health News:The 2015 China Overseas Investment and Entrepreneurship Summit (COIES) Announced 2Health News:Amada Senior Care Expands to Greater Kansas City 2Health News:Trigger Tome Surpasses 600 Successful Patient Procedures 2
... , , , , ... Inc. today announced several scientific presentations at the International ... Boston that will feature its investigational antiplatelet drug elinogrel, ... clinical development, and its oral Factor Xa inhibitor anticoagulant ...
... increases likelihood of eczema and asthma, study finds, ... defective gene significantly increases the likelihood of developing ... researchers report. , Reviewing the findings of 24 ... that mutations of the filaggrin gene -- which ...
... Pack Your Bag(TM) Events Bring Educational Outreach to Senior Centers, ... , TAMPA, Fla., July 10 Eight out of ... such as high blood pressure or diabetes. According to CVS/pharmacy, ... of eight or more prescriptions regularly. With increased use of ...
... Connectyx Technologies Holdings Group, Inc. (Other OTC: CTYX) is ... itself as the market leader in the Electronic Personal Health ... during yesterday,s Nationwide Teleconference. Mr. Schuman went on to ... million members by the end of 2011 through continually expanding ...
... Pa., July 10 The Quigley Corporation, (Nasdaq: ... , today announced that Dr. Richard Rosenbloom has resumed ... had been temporarily suspended from the Company in late May, 2009. ... Company, said, "We are pleased to have Dr. Rosenbloom again serving ...
... ... does the company take great pride in their surgical instruments, Spectrum focuses on developing customers ... Stow, OH ... June 17, 2009, for the 2nd consecutive year, the company was recipient of a ...
Cached Medicine News:Health News:Portola Pharmaceuticals Announces Several Scientific Presentations at International Society on Thrombosis and Haemostasis XII Congress 2Health News:Portola Pharmaceuticals Announces Several Scientific Presentations at International Society on Thrombosis and Haemostasis XII Congress 3Health News:Scientists Zero In on Elusive 'Allergy Gene' 2Health News:The National Council on Aging and CVS/pharmacy Educate Tampa Seniors on Medication Management and How to Save Money on Prescription Drugs 2Health News:The National Council on Aging and CVS/pharmacy Educate Tampa Seniors on Medication Management and How to Save Money on Prescription Drugs 3Health News:The National Council on Aging and CVS/pharmacy Educate Tampa Seniors on Medication Management and How to Save Money on Prescription Drugs 4Health News:Connectyx Looks to Establish Market Leadership with MedSync and MedFlash Product Line As Stated During Nationwide Teleconference 2Health News:Connectyx Looks to Establish Market Leadership with MedSync and MedFlash Product Line As Stated During Nationwide Teleconference 3Health News:Dr. Richard Rosenbloom Resumes Services To The Quigley Corporation's Pharma Subsidiary 2Health News:Dr. Richard Rosenbloom Resumes Services To The Quigley Corporation's Pharma Subsidiary 3Health News:Spectrum Surgical Instruments Receives 2009 World Class Customer Service Award 2
... technology is here! LTF™ (Layered Thin Film) ... test platform that is easy to read, ... as a credit card. What is Infectious ... reason women visit their physician. Vaginal discharge ...
... test! QuickScreen multi-panel dip cards offer minimal ... choice of any conceivable combination of 9 ... for your drug testing program. Just dip ... built-in timer tells you when to read ...
... SureStep™ Drug Screen Tests are available in ... MDMA (Ecstasy). Designed using Microgenics Antibody Technology, ... only point of care immunoassay targeted to ... both MDA and MDEA but no cross-reactivity ...
Accu-Stat Home Drug Test for Marijuana (THC), Cocaine (COC), Amphetamine (AMP), Methamphetamine (mAMP), Opiates (OPI), and Phencyclidine (PCP)....
Medicine Products: